Journals / Uluslararası Hematoloji-Onkoloji Dergisi / 2013 / Cilt: 23 - Sayı: 2

Mide Karsinoid Tümörleri: Tanı ve Tedavide Karşılaşılan Problemler

Gastric Carcinoid Tumors: The Problems Encountered in Diagnosis and Treatment

Pages
104–108
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The 5-year survival of type I and IV gastric carcinoid tumors were 69.1% and 48.6%, respectively.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Gastric carcinoid tumors are rare tumors that originate from gastric enterochromaffin-like cells in the oxyntic mucosa and constitute 3.2-4% of all carcinoid tumors.
📊
Key Findings & Data:The patients with gastric carcinoid tumors were analyzed with respect to their presenting signs and symptoms, serum gastrin level, imaging studies, operative procedures and outcome of 21 patients with gastric carcinoid tumor were enrolled in this study.
💡
Conclusion & Impact:The 5-year survival of type I and IV gastric carcinoid tumors were 69.1% and 48.6%, respectively.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Gastric carcinoid tumors are rare tumors that originate from gastric enterochromaffin-like cells in the oxyntic mucosa and constitute 3.2-4% of all carcinoid tumors. Herein, outcome of a single institution experience with gastric carcinoid tumors were evaluated retrospectively. The patients with gastric carcinoid tumors were analyzed with respect to their presenting signs and symptoms, serum gastrin level, imaging studies, operative procedures and outcome of 21 patients with gastric carcinoid tumor were enrolled in this study. Sixteen patients had type 1 and 5 had type IV gastric carcinoid tumors. Endoscopic biopsy was performed in 15 patients with type I and in 2 patients with type IV. Multifocal tumor was seen in 7 patients with type I. Preoperative serum gastrin levels were high in 11 patients with type I and 3 patients with type IV gastric carcinoid tumor. In the patients with type I gastric carcinoid tumor, endoscopic mucosal resection (EMR) was performed in 6 patients with only one tumor and the tumor size less than 1 cm. In this group, 3 patients had relapse (50%). Total gastrectomy was performed in all the patients with type IV gastric carcinoid tumor. The 5-year survival of type I and IV gastric carcinoid tumors were 69.1% and 48.6%, respectively.

Özet

Midenin karsinoid tümörleri nadir olup mide mukozasında yerleşen enterokromafin hücrelerden köken alır ve tüm karsinoid tümörlerin % 3,2- 4’ünü oluşturur. Burada tek bir merkezin mide karsinoid tümörlü hastaları retrospektif olarak değerlendirilip sonuçları sunulmuştur. Başvuru şikayetleri, bulgular, serum gastrin düzeyleri, görüntüleme çalışmaları, tedavi yaklaşımları ve sonuçları değerlendirilen 21 hasta çalışmaya dahil edilmiştir. Hastaların 16’sında tip I, 5’inde tip IV karsinoid tümör saptanmış, tip I mide karsinoid tü- mörlü 15 hastaya ve tip IV tümörlü 2 hastaya endoskopik biyopsi yapılmıştır. Tip I karsinoid tümörlü 7 hastada multifokal tümör saptanmıştır. Preoperatif serum gastrin düzeyleri tip I tümörlü 11 hastada ve tip IV tümörlü 3 hastada yüksek olarak bulunmuştur. Tip I mide karsinoid tümörlü hastalardan 1 cm boyutundan küçük tek bir tümörü olan 6 hastaya endoskopik mukozal rezeksiyon (EMR) uygulanmıştır. Bu gruptaki 3 hastada (%50) nüks saptanmıştır. Tip IV mide karsinoid tümörlü tüm hastalara total gastrektomi uygulanmıştır. Beş yıllık sağ kalım oranları tip I ve tip IV mide karsinoid tümörlü hastalarda sırasıyla %69,1 ve %48,6 olarak saptanmıştır.

🔖

Cite This Article

YÜKSEL, O., KÖKSAL, H., EKİNCİ, Ö., AKIN, M., ÖZDEMİR, E., FERAHKÖŞE, Z. (2013). Mide Karsinoid Tümörleri: Tanı ve Tedavide Karşılaşılan Problemler. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 23 - Sayı: 2, 104–108. https://ajindex.com/articles/323304

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer 79: 813-29, 1997
  2. Modlin IM, Lye KD, Kidd M. Carcinoid tumors of the stomach. Surg Oncol 12: 153-172, 2003
  3. Mulkeen A, Cha C. Gastric carcinoid. Curr Opin Oncol 17: 1-6, 2005
  4. Borch K, Ahrén B, Ahlman H, et al. Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg 242: 64-73, 2005
  5. Burkitt MD, Pritchard DM. Review article: Pathogenesis and management of gastric carcinoid tumours. Aliment Pharmacol Ther 24:1305-20, 2006
  6. Hakanson R, Tielemans Y, Chen D, et al. Time-dependent changes in enterochromaffin-like cell-kinetics in stomach of hypergastrinemic rats. Gastroenterology 105:15-21, 1993
  7. Bordi C, Dadda T, Azzoni C, et al. Hypergastrinemia and gastric enterochromaffin- like cells. Am J Surg Pathol 19:S8-S19, 1995
  8. Hakanson R, Sundler F. Proposed mechanism of induction of gastric carcinoids-the gastrin hypothesis. Eur J Clin Invest 20:S65-S71, 1990
  9. Modlin I, Tang L. The gastric enterochromaffin-like cell: an enigmatic cellular lesion. Gastroenterology 111:783-810, 1996
  10. Gough D, Thompson G, Crotty T, et al. Diverse clinical and pathologic features of gastric carcinoid and the relevance of hypergastrinemia. World J Surgery 18: 472-480, 1994
  11. Thomas RM, Baybick JH, Elsayed AM, Sobin LH. Gastric carcinoids: an immunohistochemical and clinicopathologic study of 104 patients. Cancer 73: 2053-2058, 1994
  12. Massironi S, Sciola V, Spampatti MP, et al. Gastric carcinoids: between underestimation and overtreatment. World J Gastroenterol 15: 2177-2183, 2009
  13. Ichikawa J, Tanabe S, Koizumi W, et al. Endoscopic mucosal resection in the management of gastric carcinoid tumors. Endoscopy 35: 203-206, 2003
  14. Pasieka JL. Carcinoid tumors. Surg Clin North Am 89: 1123-1137, 2009
  15. Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 25: 458-511, 2004
  16. Garland J, Buscombe JR, Bouvier C, et al. Sandostatin LAR (long-acting octreotide acetate) for malignant carcinoid syndrome: a 3-year experience. Aliment Pharmacol Ther 17: 437-444, 2003
  17. Schnirer II, Yao JC, Ajani JA. Carcinoid-a comprehensive review. Acta Oncol (Madr) 42: 672-692, 2003.